1-7 of 7
Keywords: Aromatase inhibitors
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2010) 77 (Suppl. 1): 23–37.
Published Online: 02 February 2010
.... Approximately 50% of patients with advanced disease do not respond to first-line treatment with tamoxifen, and many women who receive tamoxifen as adjuvant therapy experience tumor relapse and die from their disease. Aromatase inhibitors are proving superior to tamoxifen, at least in certain patient subsets...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1995) 52 (6): 454–457.
Published Online: 30 June 2009
... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Breast cancer Tamoxifen resistance Aromatase inhibitors Original Paper Oncology 1995;52:454-457 C. Noberascoa E...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2006) 70 (4): 301–305.
Published Online: 31 October 2006
... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Tamoxifen Triglycerides Cholesterol High-density lipoprotein Low-density lipoprotein Aromatase inhibitors Tamoxifen, a synthetic...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2005) 69 (1): 1–9.
Published Online: 01 September 2005
... with serious side effects. As adjuvant endocrine therapy is generally administered for long periods of time, the safety and tolerability of agents used in this setting are of particular importance. Due to their superior efficacy over tamoxifen, newer agents, such as the third-generation aromatase inhibitors...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1998) 55 (6): 501–507.
Published Online: 22 October 1998
...- and third-generation aromatase inhibitors and new antiestrogens have recently been introduced in the clinic or are in late development. Promising results have been obtained with new endocrine agents in third- and fourth-line treatment. Future research directions are given and the endocrine treatment...